Incyte Corporation (INCY)
Valuation Overview•Is Incyte Corporation Overvalued or Undervalued?
Priced at a premium to peer multiples and intrinsic cash flows, demanding strong execution to justify current levels.
High-quality fundamentals with a strong composite quality score of 81/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: High-quality compounder, with profitability as the only relative weakness.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
INCY demonstrates strong business quality with robust profitability and healthy margins (highlighted by a massive 51.1% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($3.0B) and minimal debt risk.
The company demonstrates solid revenue growth (14.8% 3Y CAGR) paired with highly explosive earnings growth (61.6% EPS 3Y CAGR). Operating efficiency remains adequate with margins around 11.6%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | +21.2% | +14.8% | +14.0% | +21.2% | |
| EBITDA | -$688.2M | — | +29.6% | — | — | |
| Net Income | -$784.8M | +3845.0% | +55.7% | — | +69.6% | |
| EPS (Diluted) | $-3.86 | +4173.3% | +61.6% | — | +71.0% | |
| Free Cash Flow | -$691.0M | +443.9% | +14.9% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 92.7% | 92.8% | 93.5% | 94.2% |
| Operating Margin | 11.6% | 15.4% | 16.7% | 9.6% |
| Net Margin | 6.7% | 14.0% | 16.8% | 8.8% |
| FCF Margin | 11.4% | 14.9% | 18.0% | 12.5% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q4'26Latest | $-3.93 | $-3.60 | +8.4% | ||
| Q3'26 | $2.15 | $3.09 | +43.7% | ||
| Q2'26 | $1.34 | $1.81 | +35.1% | ||
| Q1'26 | $1.90 | $1.80 | -5.3% | ||
| Q4'25 | $1.66 | $2.26 | +36.1% | ||
| Q3'25 | $1.39 | $1.57 | +12.9% | ||
| Q2'25 | $1.01 | $1.16 | +14.9% | ||
| Q1'25 | $1.57 | $1.43 | -8.9% |
Total return is +13.7% (1Y), outperforming the benchmark by +4.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +18.0% | +10.3% | — |
| 1Y | +13.7% | +4.0% | — |
| 3YCAGR | +29.9% | +10.3% | — |
| 5YCAGR | +12.5% | +2.7% | — |
| 10YCAGR | +2.6% | -10.7% | — |
The S&P 500 is at 29.9x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Incyte Corporation (INCY) valuation, health, and returns.
Incyte Corporation is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Expensive versus peers compared to industry peers. overvalued (implying -20.3% downside from DCF intrinsic value of $95.42)
Incyte Corporation has multiple valuation anchors: DCF Intrinsic Value: $95.42 | Peer Relative Fair Value: $87.59 | Wall Street Analyst Target: $137.67 (implying +15.1% upside). A convergence of these signals offers higher conviction.
Incyte Corporation displays excellent financial health with a composite quality score of 81/100, supported by a Altman Z-Score of 10.2 (safe zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 51.1%.
Incyte Corporation does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Incyte Corporation's current growth trajectory is Accelerating. The company achieved +21.2% 1Y revenue growth and +4173.3% 1Y EPS growth, compared to its 3Y revenue CAGR of +14.8%.
Wall Street consensus is Buy based on 45 analysts, beating EPS expectations in 50% of recent quarters with a 3-quarter streak. The consensus price target represents a +15.1% change from current levels.
Investment risks for Incyte Corporation include: -18.3% 1-year max drawdown. Volatility risk is characterized by a beta of 0.44x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.